August 02, 2016
1 min read
Save

Patients with psoriasis effectively switch from Remicade to infliximab biosimilar

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients with psoriasis being treated with Remicade had no significant change in clinical response and experienced minor adverse events when switching to an infliximab biosimilar, according to recently published study results.

Researchers studied two cohorts of patients with moderate-to-severe psoriasis who were treated between July 1, 2015, and Jan. 20, 2016 at the University of Turin in Italy. There were 30 patients with psoriasis having ongoing treatment with Remicade (infliximab originator, Janssen Biotech), including 10 patients who also had a diagnosis of psoriatic arthritis. The second cohort consisted of five patients for whom at least one systemic treatment failed and who had not received infliximab prior to the study.

Psoriasis Area and Severity Index (PASI) and visual analog pain scale were used as objective and subjective measurements, respectively, of disease activity.

The patients who switched from the infliximab originator to infliximab biosimilar Remsia (CT-P13, Celltrion) had a mean PASI score of 29.2 before treatment, with a median time on the infliximab originator of 237 weeks. The patients had a median follow-up on the biosimilar of 23 weeks. There was no significance difference in PASI or visual analog scale scores before the switch to biosimilar and the end of the study period (P > .05).

One patient developed herpes zoster during follow-up, with symptoms resolving after treatment. No other adverse events were reported.

Patients in the infliximab-naïve cohort had a mean PASI score of 27.3 at beginning of treatment, with four of five patients reaching 75% improvement in PASI score at week 10, the end of the induction stage.

“Despite the limitations of our study (low sample size, limited follow-up time), we conclude that the infliximab biosimilar is an appealing treatment choice for patients affected by plaque psoriasis,” the researchers wrote. “Considering possible price differences between the originator and biosimilar, its use might help lower health care spending.” – by Bruce Thiel

Disclosure: The researchers report no relevant financial disclosures.